News|Articles|May 7, 2024
Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future
Author(s)PCM Trials
In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
2
Honing the Power of AI for Next Generation Trial Oversight and Execution
3
The Value of Pragmatic Randomized Clinical Trials: Strategic Approaches for Real-World Impact
4
Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
